Switzerland· 45054020
Dr. Reckeweg R 25 Prostatan, gouttes buvables
A medicinal product containing chimaphila umbellata d3, clematis vitalba d3, conium maculatum (hab) d5, ferrosi picras d4, pareira brava d2, populus tremuloides d3, pulsatilla pratensis d3, serenoa repens (hab) d2, registered in Switzerland by Laboratoire Jacques Reboh et fils SA and dispensed under Swissmedic category D.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
The record
At a glance
Swissmedic (Switzerland)- Active substance
- chimaphila umbellata D3, clematis vitalba D3, conium maculatum (HAB) D5, ferrosi picras D4, pareira brava D2, populus tremuloides D3, pulsatilla pratensis D3, serenoa repens (HAB) D2
- Manufacturer
- Laboratoire Jacques Reboh et fils SA
- Country
- Switzerland (CH)
- ATC code
- —
- Swissmedic category
- D
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f7eb9f8c-4618-44c9-b39f-adb792f47785 GET /v1/drugs/f7eb9f8c-4618-44c9-b39f-adb792f47785?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about chimaphila umbellata d3, clematis vitalba d3, conium maculatum (hab) d5, ferrosi picras d4, pareira brava d2, populus tremuloides d3, pulsatilla pratensis d3, serenoa repens (hab) d2.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.